Scholars@Duke publication: FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.

FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.

Publication , Conference

Landi, D; Ziegler, D; Franson, A; Baxter, P; Leary, S; Larouche, V; Waanders, A; Van der Lugt, J; McCowage, G; Doz, F; Jabado, N; Zapotocky, M ...

Published in: Journal of Clinical Oncology

Published version (DOI) Link to item

FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.

Duke Scholars

Author Daniel Bryce Landi Pediatrics, Hematology-Oncology

Published In

Journal of Clinical Oncology

DOI

10.1200/JCO.2022.40.16_suppl.TPS10062

ISSN

0732-183X

Volume

Issue

Start / End Page

616s / 616s

Location

McCormick Place, Chicago, IL

Publisher

American Society of Clinical Oncology

Conference Name

58th Annual Meeting of the American Society of Clinical Oncology Annual Meeting

Related Subject Headings

Oncology & Carcinogenesis
1112 Oncology and Carcinogenesis
1103 Clinical Sciences

Citation

APA

Chicago

ICMJE

MLA

NLM

Landi, D., Ziegler, D., Franson, A., Baxter, P., Leary, S., Larouche, V., … Hansford, J. (n.d.). FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. In Journal of Clinical Oncology (Vol. 40, pp. 616s-616s). McCormick Place, Chicago, IL: American Society of Clinical Oncology. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS10062

Landi, Daniel, David Ziegler, Andrea Franson, Patricia Baxter, Sarah Leary, Valérie Larouche, Angela Waanders, et al. “FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.” In Journal of Clinical Oncology, 40:616s-616s. American Society of Clinical Oncology, n.d. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS10062.

Landi D, Ziegler D, Franson A, Baxter P, Leary S, Larouche V, et al. FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. In: Journal of Clinical Oncology. American Society of Clinical Oncology; p. 616s-616s.

Landi, Daniel, et al. “FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.” Journal of Clinical Oncology, vol. 40, no. 16, American Society of Clinical Oncology, pp. 616s-616s. Manual, doi:10.1200/JCO.2022.40.16_suppl.TPS10062.

Landi D, Ziegler D, Franson A, Baxter P, Leary S, Larouche V, Waanders A, Van der Lugt J, McCowage G, Doz F, Jabado N, Schiavello E, Zapotocky M, Cornelio I, Blackman S, Da Costa D, Cox M, Witt O, Kilburn L, Hansford J. FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. Journal of Clinical Oncology. American Society of Clinical Oncology; p. 616s-616s.